Patents by Inventor Navin Vaya
Navin Vaya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10293048Abstract: A pharmaceutical composition and preparing processes thereof. The composition comprises bortezomib or pharmaceutically acceptable salt or solvate thereof, tromethamine and an organic carboxylic acid, and the pH of the composition is from about 3.0 to 6.0.Type: GrantFiled: March 1, 2013Date of Patent: May 21, 2019Assignee: DR. REDDY'S LABORATORIES LIMITEDInventors: Navin Vaya, Harshal Prabhakar Bhagwatwar, Rakeshwar Bandichhor, Nirmal Khati, Riyaz Ahmed Shaik, Rahul Bhise, Yakaswamy Asalla, Rajkumar Bhimrao Shinde
-
Patent number: 9655885Abstract: Aspects of the present invention relate to amorphous form of mirabegron, amorphous solid dispersion of mirabegron, process for its preparation, processes for preparation of ? form crystal and ? form crystal of mirabegron and pharmaceutical composition thereof.Type: GrantFiled: April 21, 2015Date of Patent: May 23, 2017Assignee: DR. REDDY'S LABORATORIES LTD.Inventors: Vishweshwar Peddy, Rajesham Boge, Yogesh S Gattani, Nagoji Shinde, Pradip Kumar Ghosh, Sritharan Seetharaman, Navin Vaya, Vaibhav Sihorkar, Rajashekhar Totad, Krishna Venkatesh, Ganesh Arun Katkar, Snehalatha Movva, Piyush Chudiwal
-
Publication number: 20150224087Abstract: Aspects of the present invention relate to amorphous form of mirabegron, amorphous solid dispersion of mirabegron, process for its preparation, processes for preparation of ? form crystal and ? form crystal of mirabegron and pharmaceutical composition thereof.Type: ApplicationFiled: April 21, 2015Publication date: August 13, 2015Inventors: Vishweshwar PEDDY, Rajesham BOGE, Yogesh S. GATTANI, Nagoji SHINDE, Pradip Kumar GHOSH, Sritharan SEETHARAMAN, Navin VAYA, Vaibhav SIHORKAR, Rajashekhar TOTAD, Krishna VENKATESH, Ganesh Arun KATKAR, Snehalatha MOVVA, Piyush CHUDIWAL
-
Publication number: 20150051172Abstract: A pharmaceutical composition and preparing processes thereof. The composition comprises bortezomib or pharmaceutically acceptable salt or solvate thereof, tromethamine and an organic carboxylic acid, and the pH of the composition is from about 3.0 to 6.0.Type: ApplicationFiled: March 1, 2013Publication date: February 19, 2015Inventors: Navin Vaya, Harshal Prabhakar Bhagwatwar, Rakeshwar Bandichhor, Nirmal Khati, Riyaz Ahmed Shaik, Rahul Bhise, Yakaswamy Asalla, Rajkumar Bhimrao Shinde
-
Publication number: 20140142153Abstract: Aspects of the present appliction relate to pharmaceutical formulations comprising bendamustine or its pharmaceutically acceptable salts, isomers, racemates, enantiomers, hydrates, solvates, metabolites, polymorphs, and mixtures therof, suitable for phamaceutical use. Aspects further provide methods of producing stable bendamustine compositions.Type: ApplicationFiled: January 25, 2012Publication date: May 22, 2014Applicants: DR. REDDY'S LABORATORIES, INC., DR. REDDY'S LABORATORIES LTD.Inventors: Chandrasekhar Kocherlakota, Tarun Singh, Nagaraju Banda, Nirmal Khati, Sachin Sharma, Prasad Vure, Aparna Mulupuru, Navin Vaya, Amit Anil Charkha
-
Publication number: 20140051733Abstract: The present application discloses stable pharmaceutical compositions for the oral administration of febuxostat with pharmaceutical excipients which provide improved dissolution rate and polymorphic stability both while manufacturing and during storage and process for preparing the stable compositions, packaging and their use in the treatment of gout of hyperuricemia.Type: ApplicationFiled: August 12, 2013Publication date: February 20, 2014Applicant: Dr. Reddy's Laboratories Ltd.Inventors: Sunil Beeram Reddy, Amarnath Suseendharnath, Manikandan Ramalingam, Venkatesh Madhavacharya, Navin Vaya, Harshal Prabhakar Bhagwatwar, Venkateswarlu Vobalaboina
-
Patent number: 8268352Abstract: A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise additionally another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.Type: GrantFiled: May 19, 2005Date of Patent: September 18, 2012Assignee: Torrent Pharmaceuticals LimitedInventors: Navin Vaya, Rajesh Singh Karan, Sunil Sadanand Nadkarni, Vinod Kumar Gupta
-
Patent number: 8263125Abstract: A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form.Type: GrantFiled: May 19, 2005Date of Patent: September 11, 2012Assignee: Torrent Pharmaceuticals LimitedInventors: Navin Vaya, Rajesh Singh Karan, Sunil Sadanand Nadkarni, Vinod Kumar Gupta
-
Patent number: 8216609Abstract: A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents; a process for preparing the dosage form.Type: GrantFiled: July 29, 2003Date of Patent: July 10, 2012Assignee: Torrent Pharmaceuticals LimitedInventors: Navin Vaya, Rajesh Singh Karan, Sunil Sadanand Nadkarni, Vinod Kumar Gupta
-
Publication number: 20120121700Abstract: Pharmaceutical formulations prepared by granulating valganciclovir or a salt thereof, using a nonaqueous solvent or hydro-alcohol.Type: ApplicationFiled: November 14, 2011Publication date: May 17, 2012Inventors: Vaibhav Dubey, Mamta Mishra, Ramakant Gundu, Navin Vaya, Harshal Prabhakar Bhagwatwar
-
Publication number: 20120058194Abstract: Stabilized substituted benzimidazole modified release pharmaceutical formulations with at least two drug-containing fractions, wherein the release from a first fraction precedes the release from a second fraction, pharmaceutical excipients, processes for preparing the stable formulations, packaging therefor, and their use in treatment of erosive esophagitis and heartburn associated with non-erosive gastroesophageal reflux disease.Type: ApplicationFiled: August 25, 2011Publication date: March 8, 2012Inventors: Navin Vaya, Mamta Mishra, Atul Shivaji Shinde, Harshal Prabhakar Bhagwatwar, Debashis Dash, Deepti Jain, Rahul Sudhakar Gawande, Vishal Lad, Sushant Dube, Venkateswarlu Vobalaboina, Srinivas Irukulla, Manikandan Ramalingam
-
Patent number: 7985422Abstract: A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form.Type: GrantFiled: July 29, 2003Date of Patent: July 26, 2011Assignee: Torrent Pharmaceuticals LimitedInventors: Navin Vaya, Rajesh Singh Karan, Sunil Sadanand Nadkarni, Vinod Kumar Gupta
-
Patent number: 7976871Abstract: A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise additionally another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.Type: GrantFiled: May 19, 2005Date of Patent: July 12, 2011Assignee: Torrent Pharmaceuticals LimitedInventors: Navin Vaya, Rajesh Singh Karan, Sunil Sadanand Nadkarni, Vinod Kumar Gupta
-
Patent number: 7939102Abstract: Rapidly disintegrating multiparticulate controlled release formulations of lamotrigine having an improved pharmacokinetic profile and improved patient compliance, and process of preparing the formulations. It provides better control of blood plasma levels than conventional tablet formulations that is administered once or more times a day.Type: GrantFiled: June 2, 2003Date of Patent: May 10, 2011Assignees: Torrent Pharmaceuticals Ltd., Torrent Pharmaceuticals Torrent Research CenterInventors: Sunil Sadanand Nadkarni, Navin Vaya
-
Publication number: 20060153916Abstract: A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form.Type: ApplicationFiled: August 1, 2003Publication date: July 13, 2006Inventors: Navin Vaya, Rajesh Karan, Sunil Nadkarni, Vinod Qupta
-
Publication number: 20060024365Abstract: A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form.Type: ApplicationFiled: May 19, 2005Publication date: February 2, 2006Inventors: Navin Vaya, Rajesh Karan, Sunil Sadanand, Vinod Gupta
-
Publication number: 20060018934Abstract: A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise additionally another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.Type: ApplicationFiled: May 19, 2005Publication date: January 26, 2006Inventors: Navin Vaya, Rajesh Karan, Sunil Nadkarni, Vinod Gupta
-
Publication number: 20060018933Abstract: A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise additionally another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.Type: ApplicationFiled: May 19, 2005Publication date: January 26, 2006Inventors: Navin Vaya, Rajesh Karan, Sunil Nadkarni, Vinod Gupta
-
Publication number: 20040096501Abstract: A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents; a process for preparing the dosage form.Type: ApplicationFiled: July 29, 2003Publication date: May 20, 2004Inventors: Navin Vaya, Rajesh Singh Karan, Sunil Sadanand Madkarni, Vinod Kumar Gupta
-
Publication number: 20040096499Abstract: A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form.Type: ApplicationFiled: July 29, 2003Publication date: May 20, 2004Inventors: Navin Vaya, Rajesh Singh Karen, Sunil Sadanand Nadkarni, Vinod Kumar Gupta